^
No biomarker
T Cell Non-Hodgkin Lymphoma
nelarabine
Sensitive: A1 - Approval
TNFRSF8 positive
Cutaneous T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
No biomarker
Cutaneous T-cell Lymphoma
bexarotene oral
Sensitive: A1 - Approval
TNFRSF8 expression
Peripheral T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
No biomarker
Peripheral T-cell Lymphoma
belinostat
Sensitive: A1 - Approval
No biomarker
Peripheral T-cell Lymphoma
pralatrexate
Sensitive: A1 - Approval
No biomarker
Peripheral T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
No biomarker
Cutaneous T-cell Lymphoma
vorinostat
Sensitive: A1 - Approval
IL2RA expression
Cutaneous T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
No biomarker
Peripheral T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
No biomarker
Cutaneous T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
ALK positive
Peripheral T-cell Lymphoma
crizotinib
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
etoposide IV
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
cyclophosphamide oral
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
cyclophosphamide oral + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
bortezomib
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
bendamustine
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
lenalidomide
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
RP6530
Sensitive: B - Late Trials
No biomarker
Cutaneous T-cell Lymphoma
RP6530
Sensitive: B - Late Trials
ALK negative
T Cell Non-Hodgkin Lymphoma
brentuximab vedotin
Sensitive: B - Late Trials
No biomarker
T Cell Non-Hodgkin Lymphoma
CS1001
Sensitive: B - Late Trials
TNFRSF8 expression
T Cell Non-Hodgkin Lymphoma
brentuximab vedotin
Sensitive: B - Late Trials
IL2RA expression
Peripheral T-cell Lymphoma
denileukin diftitox
Sensitive: C1 - Off-label
TNFRSF8 expression
Cutaneous T-cell Lymphoma
brentuximab vedotin
Sensitive: C1 - Off-label
PD-L1 overexpression
Peripheral T-cell Lymphoma
GB226
Sensitive: C3 – Early Trials
PD-1 overexpression
Peripheral T-cell Lymphoma
nivolumab
Sensitive: C3 – Early Trials
RHOA mutation
Peripheral T-cell Lymphoma
copanlisib
Sensitive: C3 – Early Trials
IDH2 mutation
Peripheral T-cell Lymphoma
copanlisib
Sensitive: C3 – Early Trials
PD-L1 underexpression
Cutaneous T-cell Lymphoma
durvalumab + lenalidomide
Sensitive: C3 – Early Trials
TSC2 mutation
Peripheral T-cell Lymphoma
copanlisib
Sensitive: C3 – Early Trials
TNFRSF8 positive
Peripheral T-cell Lymphoma
BV-ICE
Sensitive: C3 – Early Trials
IL10-H
Peripheral T-cell Lymphoma
CHOP
Resistant: C3 – Early Trials
PAK1 overexpression
T Cell Non-Hodgkin Lymphoma
FRAX597 + PF-3758309
Resistant: C3 – Early Trials
VAV1 mutation
T Cell Non-Hodgkin Lymphoma
dasatinib
Sensitive: C3 – Early Trials
RHOA G17V
T Cell Non-Hodgkin Lymphoma
dasatinib
Sensitive: C3 – Early Trials
CXCL12 overexpression
T Cell Non-Hodgkin Lymphoma
tipifarnib
Sensitive: C3 – Early Trials
KIR3DL2 Q386E
T Cell Non-Hodgkin Lymphoma
tipifarnib
Sensitive: C3 – Early Trials
KIR3DL2 C336R
T Cell Non-Hodgkin Lymphoma
tipifarnib
Sensitive: C3 – Early Trials
RPS6 underexpression
Peripheral T-cell Lymphoma
ruxolitinib
Sensitive: C3 – Early Trials
RPS6 underexpression
Cutaneous T-cell Lymphoma
ruxolitinib
Sensitive: C3 – Early Trials
ICOS underexpression
Cutaneous T-cell Lymphoma
durvalumab
Sensitive: C3 – Early Trials
PD-1 overexpression
Cutaneous T-cell Lymphoma
pembrolizumab
Sensitive: C3 – Early Trials
DNMT3A mutation
T Cell Non-Hodgkin Lymphoma
lenalidomide
Resistant: C3 – Early Trials
IDH2 mutation
T Cell Non-Hodgkin Lymphoma
lenalidomide
Resistant: C3 – Early Trials
TET2 mutation
T Cell Non-Hodgkin Lymphoma
lenalidomide
Resistant: C3 – Early Trials
TNFRSF8 negative
Peripheral T-cell Lymphoma
chidamide
Sensitive: C3 – Early Trials
TNFRSF8 negative
Peripheral T-cell Lymphoma
rituximab + lenalidomide + brentuximab vedotin
Sensitive: C4 – Case Studies
CD20 overexpression
Peripheral T-cell Lymphoma
CVAD
Resistant: C4 – Case Studies
CD20 overexpression
Peripheral T-cell Lymphoma
rituximab
Sensitive: C4 – Case Studies
CD20 overexpression
Peripheral T-cell Lymphoma
CEOP-E
Resistant: C4 – Case Studies
NPM1-ALK fusion
T Cell Non-Hodgkin Lymphoma
ceritinib
Sensitive: C4 – Case Studies
CD20 overexpression
Peripheral T-cell Lymphoma
DICE
Resistant: C4 – Case Studies
ALK positive
T Cell Non-Hodgkin Lymphoma
ceritinib
Sensitive: D – Preclinical
ALK fusion
T Cell Non-Hodgkin Lymphoma
gilteritinib
Sensitive: D – Preclinical
NPM1-ALK fusion
T Cell Non-Hodgkin Lymphoma
gilteritinib
Sensitive: D – Preclinical
CD70 overexpression
T Cell Non-Hodgkin Lymphoma
SGN-CD70A
Sensitive: D – Preclinical
ALK positive
T Cell Non-Hodgkin Lymphoma
CFT7455
Sensitive: D – Preclinical